Torrent is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $12.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Torrent's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | FDA-approved 22 Aug 2024; launched Jul 2025 | $7.7B |
| Opsumit | Johnson & Johnson | Generic | 2026 | FDA-approved 5 Aug 2024 | $2.3B |
| Otezla | Amgen | Generic | 2028 | FDA-approved 20 Jun 2025, not marketed; settled 2021, terms confidential | $2.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Torrent's share of it.
Torrent sells US copies of one of these drugs: Entresto (since Jul 2025). It also has FDA approval for Otezla and Opsumit, with no US launch confirmed. It has settled with the brand owner over 1 drug. Of the 70 makers we follow, 25 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.